|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.68 - 8.68|
|52 Week Range||8.46 - 9.11|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.31 (3.61%)|
|Ex-Dividend Date||Jul 15, 2020|
|1y Target Est||N/A|
An experimental coronavirus vaccine developed by West China Hospital has entered a mid-stage human test, authorities of China's southwestern province of Sichuan said on Tuesday. A Phase 2 trial to evaluate the safety and ability to trigger immune response of the hospital's candidate, taking place from Nov. 17, is expected to recruit 960 participants aged older than 18, the Chinese Clinical Trial Registry data showed. Shanghai Pharmaceuticals Holding , which has invested in a firm jointly developing the vaccine, said on Monday that Phase 1 and Phase 2 trials could complete within this year.
ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.